DIFICLIR proven to be clinically and cost-effective compared to standard of care in patients with CDI

New analysis from a unique real-world study demonstrates that first-line use of fidaxomicin, is clinically effective in reducing recurrence rates and lowering mortality, and provides cost savings for the treatment of potentially fatal Clostridium difficile infection (CDI).
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Cost effectiveness cdi fidaxomicin hospital hygiene protocols Latest News Source Type: news